{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:27:37Z","timestamp":1776133657222,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40264-020-00975-8","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T13:22:47Z","timestamp":1596460967000},"page":"1277-1285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-0426","authenticated-orcid":false,"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-9595","authenticated-orcid":false,"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"2018","key":"975_CR1","first-page":"1374821","volume":"24","author":"T Rabe","year":"2018","unstructured":"Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg HR, De Wilde RL, Wallwiener M. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018;24(2018):1374821.","journal-title":"Biomed Res Int"},{"key":"975_CR2","doi-asserted-by":"publisher","unstructured":"Ulipristal acetate (Esmya): restrictions on use. Drug Ther Bull. 2018;56(11):127. https:\/\/doi.org\/10.1136\/dtb.2018.11.000033.","DOI":"10.1136\/dtb.2018.11.000033"},{"key":"975_CR3","unstructured":"European Medicines Agency. Esmya Article-20 procedure - Scientific conclusions. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/esmya-article-20-procedure-scientific-conclusions_en.pdf. Accessed 12 Apr 2020."},{"key":"975_CR4","unstructured":"European Medicines Agency. Esmya: new measures to minimise risk of rare but serious liver injury. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_en-0.pdf. Accessed 12 Apr 2020."},{"issue":"4","key":"975_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","volume":"110","author":"J Donnez","year":"2018","unstructured":"Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110(4):593\u20135. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.06.044.","journal-title":"Fertil Steril"},{"issue":"12","key":"975_CR6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/14740338.2018.1550070","volume":"17","author":"J Donnez","year":"2018","unstructured":"Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225\u201332. https:\/\/doi.org\/10.1080\/14740338.2018.1550070.","journal-title":"Expert Opin Drug Saf."},{"key":"975_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2019.1680626","author":"S Del Forno","year":"2019","unstructured":"Del Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, Raimondo D, Paradisi R, Seracchioli R. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. Gynecol Endocrinol. 2019. https:\/\/doi.org\/10.1080\/09513590.2019.1680626(Epub ahead of print).","journal-title":"Gynecol Endocrinol."},{"key":"975_CR8","unstructured":"European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/ulipristal-acetate-5mg-medicinal-products-article-31-referral-review-started_en.pdf. Accessed 11 Apr 2020."},{"key":"975_CR9","unstructured":"European Medicines Agency. Designated Medical Event (DME) list. 2016. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management#designated-medical-events-section. Accessed 8 Apr 2020."},{"issue":"12","key":"975_CR10","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1177\/1352458518799598","volume":"25","author":"IC Antonazzo","year":"2019","unstructured":"Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, Muratori L, De Ponti F, Raschi E. Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler. 2019;25(12):1633\u201340. https:\/\/doi.org\/10.1177\/1352458518799598.","journal-title":"Mult Scler."},{"issue":"2","key":"975_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/hep.28323","volume":"63","author":"ES Bj\u00f6rnsson","year":"2016","unstructured":"Bj\u00f6rnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590\u2013603.","journal-title":"Hepatology"},{"issue":"6","key":"975_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1345\/aph.10397","volume":"35","author":"RM DeHart","year":"2001","unstructured":"DeHart RM, Morehead MS. Mifepristone. Ann Pharmacother. 2001;35(6):707\u201319.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"975_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","volume":"41","author":"P Periti","year":"2002","unstructured":"Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485\u2013504.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"975_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3389\/fphar.2019.01235","volume":"24","author":"E Raschi","year":"2019","unstructured":"Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4\/6 inhibitors. Front Pharmacol. 2019;24(10):1235. https:\/\/doi.org\/10.3389\/fphar.2019.01235.","journal-title":"Front Pharmacol."},{"key":"975_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"key":"975_CR16","doi-asserted-by":"publisher","unstructured":"Ivanov S.M., Lagunin A.A., Rudik A.V., Filimonov D.A., Poroikov V.V. ADVERPred\u2013web service for prediction of adverse effects of drugs. Journal of Chemical Information and Modeling, 2018; 58(1): 8\u201311 (https:\/\/doi.org\/10.1021\/acs.jcim.7b00568). http:\/\/www.way2drug.com\/adverpred\/. Accessed 11 Apr 2020.","DOI":"10.1021\/acs.jcim.7b00568"},{"key":"975_CR17","doi-asserted-by":"publisher","unstructured":"Montanari F, Knasm\u00fcller B, Kohlbacher S, Hillisch C, Baierov\u00e1 C, Grandits M, Ecker GF. Vienna LiverTox workspace-a set of machine learning models for prediction of interactions profiles of small molecules with transporters relevant for regulatory agencies. Front Chem. 2020;7:899. https:\/\/doi.org\/10.3389\/fchem.2019.00899. https:\/\/livertox.univie.ac.at\/. Accessed 11 Apr 2020.","DOI":"10.3389\/fchem.2019.00899"},{"issue":"3","key":"975_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.28678","volume":"64","author":"M Chen","year":"2016","unstructured":"Chen M, Borlak J, Tong W. A Model to predict severity of drug-induced liver injury in humans. Hepatology. 2016;64(3):931\u201340. https:\/\/doi.org\/10.1002\/hep.28678.","journal-title":"Hepatology"},{"issue":"6","key":"975_CR19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1053\/j.gastro.2017.03.012","volume":"152","author":"P Mishra","year":"2017","unstructured":"Mishra P, Chen M. Direct-acting antivirals for chronic hepatitis C: can drug properties signal potential for liver injury? Gastroenterology. 2017;152(6):1270\u20134. https:\/\/doi.org\/10.1053\/j.gastro.2017.03.012.","journal-title":"Gastroenterology"},{"issue":"1","key":"975_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17425255.2018.1417389","volume":"14","author":"S Ferrero","year":"2018","unstructured":"Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018;14(1):107\u201316. https:\/\/doi.org\/10.1080\/17425255.2018.1417389.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"4","key":"975_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/1933719114549850","volume":"22","author":"O Pohl","year":"2015","unstructured":"Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015;22(4):476\u201383. https:\/\/doi.org\/10.1177\/1933719114549850.","journal-title":"Reprod Sci."},{"issue":"2","key":"975_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0301-2115(01)00522-X","volume":"101","author":"NN Sarkar","year":"2002","unstructured":"Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol. 2002;101(2):113\u201320.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"975_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003088-199733010-00002","volume":"33","author":"O Heikinheimo","year":"1997","unstructured":"Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33(1):7\u201317.","journal-title":"Clin Pharmacokinet"},{"key":"975_CR24","unstructured":"https:\/\/www.drugbank.ca\/. Accessed 11 Apri 2020."},{"key":"975_CR25","unstructured":"European Medicines Agency. Assessment report on Esyma, May 17, 2018. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/esmya-article-20-procedure-prac-assessment-report_en.pdf. Accessed 12 April 2020."},{"issue":"3","key":"975_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.109.162651","volume":"332","author":"RA Roth","year":"2010","unstructured":"Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity\u2013two villains or one? J Pharmacol Exp Ther. 2010;332(3):692\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"975_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.02.008","author":"L Meunier","year":"2020","unstructured":"Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, Dominique HB. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 2020. https:\/\/doi.org\/10.1016\/j.clinre.2020.02.008(Epub ahead of print).","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"3","key":"975_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.14740\/gr1188","volume":"12","author":"I Shah","year":"2019","unstructured":"Shah I, Putnam T, Daugherty E, Vyas N, Chuang KY. Mifepristone: an uncommon cause of drug-induced liver injury. Gastroenterol Res. 2019;12(3):181\u20134. https:\/\/doi.org\/10.14740\/gr1188.","journal-title":"Gastroenterol Res."},{"issue":"6","key":"975_CR29","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/hep.30465","volume":"69","author":"K Funke","year":"2019","unstructured":"Funke K, Rockey DC. Cholestatic drug-induced liver injury caused by mifepristone. Hepatology. 2019;69(6):2704\u20136. https:\/\/doi.org\/10.1002\/hep.30465.","journal-title":"Hepatology"},{"key":"975_CR30","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Leuprolide. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. 2018."},{"issue":"1","key":"975_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","volume":"79","author":"FR P\u00e9rez-L\u00f3pez","year":"2014","unstructured":"P\u00e9rez-L\u00f3pez FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, Tremollieres F, Rees M, EMAS. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106\u201316. https:\/\/doi.org\/10.1016\/j.maturitas.2014.06.002.","journal-title":"Maturitas."},{"issue":"10","key":"975_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jogc.2019.01.010","volume":"41","author":"PY Laberge","year":"2019","unstructured":"Laberge PY, Murji A, Vilos GA, Allaire C, Leyland N, Singh SS. Guideline No. 389-medical management of symptomatic uterine leiomyomas\u2014an addendum. J Obstet Gynaecol Can. 2019;41(10):1521\u20134. https:\/\/doi.org\/10.1016\/j.jogc.2019.01.010.","journal-title":"J Obstet Gynaecol Can."},{"key":"975_CR33","doi-asserted-by":"publisher","first-page":"CD000547","DOI":"10.1002\/14651858.cd000547.pub2","volume":"11","author":"A Lethaby","year":"2017","unstructured":"Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11:CD000547. https:\/\/doi.org\/10.1002\/14651858.cd000547.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"975_CR34","doi-asserted-by":"publisher","first-page":"e0186158","DOI":"10.1371\/journal.pone.0186158","volume":"12","author":"I de Milliano","year":"2017","unstructured":"de Milliano I, Twisk M, Ket JC, Huirne JA, Hehenkamp WJ. Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis. PLoS One. 2017;12(10):e0186158. https:\/\/doi.org\/10.1371\/journal.pone.0186158(eCollection 2017).","journal-title":"PLoS One."},{"issue":"2","key":"975_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ijgo.12868","volume":"146","author":"M Ghonim","year":"2019","unstructured":"Ghonim M, Magdy R, Sabbour M, Ghonim M, Nabhan A. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynaecol Obstet. 2019;146(2):141\u20138. https:\/\/doi.org\/10.1002\/ijgo.12868.","journal-title":"Int J Gynaecol Obstet"},{"key":"975_CR36","first-page":"98","volume":"110","author":"U Indraccolo","year":"2019","unstructured":"Indraccolo U, Conzadori S, Greco P. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements. Recent Prog Med. 2019;110:98\u20139.","journal-title":"Recent Prog Med"},{"issue":"6","key":"975_CR37","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154\u201364.","journal-title":"Gut"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00975-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:50:13Z","timestamp":1627948213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00975-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00975-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"3 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ER, EP & FDP at the University of Bologna are supported by institutional research funds (Ricerca Fondamentale Orientata). The study was not funded in whole or in part by any research grant or funding body.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MG, EP, FDP, and ER have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data supporting the findings of this study were derived from the following resource, which is available in the public domain: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ER made substantial contributions to the conception and design of the study. MG made substantial contributions to the acquisition and analysis of data. MG, ER, EP, and FDP made substantial contributions to interpretation of the data. MG was involved in drafting the manuscript. ER, EP, and FDP made substantial contributions to critically revising the manuscript for important intellectual content. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}